Issues

Our work clearly demonstrates the modulatory impact of BRB on both gut and oral microbiomes within a DBP-induced OSCC mouse model and paves the way for future research examining a causal role of BRB–microbiota interactions at different stages of disease progression.

The proposed model can reduce interobserver variability in BI-RADS density assessment, thereby providing more standard and consistent density assessment for use in decisions about supplemental screening and risk assessment.

We evaluated the potential of erlotinib in preventing cancer by performing a randomized, double-blind, placebo-controlled trial of weekly erlotinib therapy in participants undergoing surgical removal of suspected noninvasive bladder neoplasia. Weekly erlotinib therapy was tolerated with common grade 1 to 2 toxicities but without evidence of beneficial effect upon urothelial tissue.

Li–Fraumeni syndrome (LFS) essentially guarantees a cancer diagnosis in an affected individual’s lifetime. Findings of this study reveal a difficulty for patients with LFS to adhere to recommended rigorous surveillance protocols and question how identified barriers can be broken down to reduce the morbidity and mortality of LFS.